SOURCE: Eugene Science

March 02, 2006 08:00 ET

Eugene Science, Inc. Announces Receipt of Initial Production Order for CholZero™ Capsules

LOS ANGELES, CA -- (MARKET WIRE) -- March 2, 2006 -- Eugene Science, Inc. (OTC BB: EUSI) announced today that Nutra Nano Tech, Inc., a product marketing and distribution company headquartered in Los Angeles, California, placed an initial production order with Eugene Science to launch the "CholZero™" product line in the United States. Eugene Science expects Nutra Nano Tech to launch the CholZero™ product line in the United States in April 2006.

Nutra Nano Tech recently completed an 8-week independent research study in the United States on CholZero™ and its cholesterol-lowering effects. Participants in the research study were instructed not to change anything about their lifestyle and diet other than to take CholZero™ capsules as directed for a period of 60 days. The research study revealed that participants using the CholZero™ capsules, on average, saw their total blood cholesterol levels drop by 19%, their LDL, or "bad cholesterol," levels drop by 35%, their HDL, or "good cholesterol," levels increase by 43%, and their triglyceride levels drop by 48%.

Paul Kim, President of Nutra Nano Tech, stated that, "[h]onestly speaking, we somewhat presumed that we would have good results based on the product's clinical trials. However, we were truly ecstatic with what CholZero™ capsules delivered by exceeding our expectations. Everything is on track to bring this amazing product to the U.S. market. We are eagerly looking forward to our launch and being given the opportunity to help people with their cholesterol levels naturally."

Nutra Nano Tech is a product marketing and distribution company focused on the direct response industry. Nutra Nano Tech owns the exclusive license for the CholZero™ product line in the North American market.

Eugene Science is a global biotechnology company focused on tackling ailments such as heart disease, obesity and diabetes though technological innovations and product developments in the nutraceutical field. As a first commercialization project against heart disease, Eugene Science has developed a nanoscience-based product called CZ™, a cholesterol-lowering functional food ingredient for health-conscious consumers. Eugene Science intends to license its "CZ Series" brand of cholesterol-lowering ingredients to companies worldwide. Eugene Science is headquartered in Bucheon, Kyunggi-Do, Korea, and was founded July 1997. For additional information, please visit Eugene Science's website at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Eugene Science's management's current expectations and are subject to risks, uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Eugene Science as of the date of the press release, and Eugene Science assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Eugene Science's results of operations is detailed in Eugene Science's filings with the United States Securities and Exchange Commission available at

Contact Information

  • Contact:
    Mark Bernhard
    Capital Group Communications
    (415) 843-0200
    Email Contact